ADC-HER2s consist of a monoclonal antibody that delivers a chemotherapy molecule directly to HER2-expressing tumor cells, resulting in the targeted killing of cancer cells while minimizing damage to healthy cells [15]. This evidence concerns the gene ERBB2 and neoplasm.